Fate Therapeutics (FATE) Tops Q2 EPS by 5c, misses on revenue

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $5.41 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman starts Talen at buy, sees PJM power tightness boosting earnings
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight